Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: A randomized, placebo-controlled study

被引:14
作者
Bautista, JL
Bugos, C
Dirnberger, G
Atherton, T
机构
[1] Bautista Med Grp, Fresno, CA 93721 USA
[2] Aventis Pharmaceut Inc, Bridgewater, NJ USA
[3] Quintiles Inc, Kansas City, MO USA
关键词
type; 2; diabetes; glimepiride; Mexican American; fasting plasma glucose; hemoglobin A(1c); randomized trial;
D O I
10.1016/S0149-2918(03)90025-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Mexican Americans, the fastest growing ethnic group in the United States, have a 2- to 3-fold higher prevalence of type 2 diabetes mellitus relative to the non-Hispanic white population. It is estimated that 10% of Mexican Americans greater than or equal to20 years of age have diabetes. Objective: The goal of this study was to evaluate the efficacy and safety of glimepiride, a long-acting sulfonylurea, as an adjunct to diet/exercise in Mexican Americans with type 2 diabetes mellitus. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study. Mexican Americans with uncontrolled type 2 diabetes, defined as a fasting plasma glucose (FPG) level between 120 mg/dL and 225 mg/dL and glycated hemoglobin (HbA(1c)) values between 8.0% and 10.5%, after greater than or equal to3 months of diet/exercise were enrolled. Patients were randomized in a 2:1 ratio (using the lowest available treatment assignment number when eligibility was established) to receive 14 weeks of glimepiride or matching placebo once daily with continued diet/exercise. The starting glimepiride dose was 1 mg, with titration to 2 mg and 4 mg for FPG levels >120 mg/dL. The primary efficacy variable was change in HbA(1c) from baseline to study end point. Secondary efficacy variables were HbA(1c) response (rated as excellent, good, or marginal) and changes in FPG, fasting insulin, fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) levels from baseline to study end point. The tolerability of glimepiride in this study population was determined by evaluating adverse events, hypoglycemic episodes, and physical examination as well as laboratory findings. All analyses were performed on an intent-to-treat basis. A per-protocol analysis also was conducted to support the primary efficacy analysis. Results: Seventy patients were randomized to treatment with glimepiride (n = 48) or placebo (n = 22). The glimepiride and placebo groups were similar with respect to mean (SE) age (48.4 [11.7] and 50.7 [10.0] years, respectively) and sex (56.3% [27/48] and 50.0% [11/22] were male, respectively). However, the glimepiride group had a higher mean body weight (83.3 [17.0] vs 76.3 [18.5] kg) and a significantly higher mean fasting insulin level (23.8 [17.7] vs; 17.8 [19.7] muU/mL; P = 0.031). The mean (SE) HbA(1c) values at study end point were 7.8% (0.2%) and 9.9% (0.7%) in patients receiving glimepiride and placebo, respectively The adjusted mean difference in HbA(1c) reduction from baseline to end point was statistically significant in favor of glimepiride (-1.8% [0.4%]; P < 0.001). More pronounced HbA(1c) impairment at baseline was associated with greater glimepiride-placebo differences in HbA(1c) reduction. Glimepiride-treated patients also achieved a significantly greater improvement in FPG, with an adjusted mean (SE) treatment difference of -46.7 (16.7) mg/dL (P = 0.007). Glimepiride did not appear to affect fibrinogen and PAI-1 levels but was associated with significantly greater mean increases in fasting insulin (10.2 vs -2.1 muU/mL; P = 0.002) and body weight (2.3 vs 2.1 kg; P < 0.001) compared with placebo. Glimepiride was well tolerated, with an adverse-event profile similar to that of placebo. Conclusions: These results indicate that once-daily glimepiride plus diet/ exercise was effective in Mexican Americans with type 2 diabetes whose disease was inadequately controlled with diet/exercise alone. It appeared to be well tolerated in the population studied. More weight gain was seen with glimepiride compared with placebo. Given the high prevalence of type 2 diabetes among Mexican Americans, further clinical studies of glimepiride and other glucose-lowering therapies are needed in this ethnic subset. Copyright (C) 2003 Excerpta Medica, Inc.
引用
收藏
页码:194 / 209
页数:16
相关论文
共 50 条
  • [21] Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials
    Singh, Awadhesh Kumar
    Singh, Akriti
    Singh, Ritu
    Misra, Anoop
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (02)
  • [22] Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study
    Ji, Linong
    Li, Ling
    Ma, Jianhua
    Li, Xuefeng
    Li, Dongmei
    Meng, Bangzhu
    Lu, Weiping
    Sun, Jiao
    Liu, Yanmei
    Takayanagi, Gen
    Wang, Yi
    [J]. ENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (02)
  • [23] Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
    Kawamori, Ryuzo
    Haneda, Masakazu
    Suzaki, Keiko
    Cheng, Gang
    Shiki, Kosuke
    Miyamoto, Yuki
    Solimando, Fernando
    Lee, Christopher
    Lee, Jisoo
    George, Jyothis
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (09) : 2200 - 2209
  • [24] Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial
    Kaku, Kohei
    Haneda, Masakazu
    Tanaka, Yuko
    Lee, Ganghyuck
    Shiki, Kosuke
    Miyamoto, Yuki
    Solimando, Fernando
    Lee, Jisoo
    Lee, Christopher
    George, Jyothis
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (01) : 136 - 145
  • [25] Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin
    Frias, Juan P.
    Wynne, Alan G.
    Matyjaszek-Matuszek, Beata
    Bartaskova, Dagmar
    Cox, David A.
    Woodward, Brad
    Li, Ying G.
    Tham, Lai S.
    Milicevic, Zvonko
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (09) : 2048 - 2057
  • [26] Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
    Ishihara, Hisamitsu
    Yamaguchi, Susumu
    Nakao, Ikko
    Okitsu, Akira
    Asahina, Seitaro
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (12) : 1207 - 1216
  • [27] Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials
    Hagi, Katsuhiko
    Kochi, Kenji
    Watada, Hirotaka
    Kaku, Kohei
    Ueki, Kohjiro
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (09) : 1101 - 1109
  • [28] Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Sone, Hirohito
    Kaneko, Tatsuroh
    Shiki, Kosuke
    Tachibana, Yoshifumi
    Pfarr, Egon
    Lee, Jisoo
    Tajima, Naoko
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (03) : 417 - 426
  • [29] Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials
    Rehman, M. B.
    Tudrej, B. V.
    Soustre, J.
    Buisson, M.
    Archambault, P.
    Pouchain, D.
    Vaillant-Roussel, H.
    Gueyffier, F.
    Faillie, J. -L.
    Perault-Pochat, M. -C.
    Cornu, C.
    Boussageon, R.
    [J]. DIABETES & METABOLISM, 2017, 43 (01) : 48 - 58
  • [30] Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial
    Guo Qiang
    Zhang Hengyao
    Li Mindian
    Zhao Ziyi
    Luo Yunlin
    Luo Yulei
    Cao Wenzhai
    Zhao Huan
    Zhu Ranran
    Lei Xingxing
    Chen Huizhen
    Gan Huakui
    Zuo Zhihuang
    Chen Qi
    Shi Cuimei
    Zhang Xinli
    Guo Jian
    Zhong Sen
    Chen Qiu
    [J]. JournalofTraditionalChineseMedicine, 2016, 36 (05) : 640 - 648